Risperidone in the Treatment of Children and Adolescents with Schizophrenia: A Retrospective Study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Risperidone is a newly available atypical antipsychotic agent that has been reported to be associated with fewer extrapyramidal side effects (EPS) than conventional neuroleptics in adults with schizophrenia. This study assessed the safety and efficacy of risperidone in 16 children and adolescents (aged 9-20 years, mean 14.9 years) who were clinically diagnosed with psychotic disorders: 13 patients met DSM-III-R criteria for schizophrenia, 2 met criteria for schizoaffective disorder, and 1 had schizophreniform disorder. Eleven of the 16 patients had previous unsuccessful neuroleptic trials. Patient charts were reviewed by the patients' child and adolescent psychiatrist for diagnoses, clinical changes, and adverse events. Clinical response was assessed retrospectively using the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression (CGI) scale. With the risperidone dose titrated gradually, an optimal clinical response was found at a mean daily risperidone dose of 5.93 mg (range 2-10 mg). All but one of the 16 patients had an adequate clinical response to risperidone therapy. Statistically significant improvements were found in the CGI (p < 0.0001), the BPRS Total Score (p < 0.0001), and the BPRS Negative Symptom Score (p < 0.001). In general, only mild drug-induced side effects were experienced, with 5 patients developing mild sedation and 3 developing EPS. Risperidone appeared to be safe and effective in ameliorating symptoms of schizophrenia in this age group. It is speculated that the gradual titration of risperidone was crucial in achieving a relatively low rate of EPS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Influence of Age and Sex on the Onset and Early Course of Schizophrenia
Häfner, H., Maurer, K., Löffler, W., & Riecher-Rössler, A. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.1.80 · Cited by 644
Cited by
Effective Treatment for Mental Disorders in Children and Adolescents
Burns, B. J., Hoagwood, K., & Mrazek, P. J. (1999) · Clinical Child and Family Psychology Review · doi:10.1023/a:1021826216025 · Cited by 385
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & Stock, S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.02.008 · Cited by 361
Second-Generation Antipsychotic Medications in Children and Adolescents
Cheng-Shannon, J., McGough, J. J., Pataki, C., & McCracken, J. T. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.372 · Cited by 152
Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods
McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180691779 · Cited by 90
“Published reports support their benefit for this population (Armenteros et al., 1997; Findling et al., 2003; Grcevich et al., 1996; Kumra et al., 1998; Shaw et al., 2006; Simeon et al., 1995).”
BackgroundSelf-citationPaediatric uses of atypical antipsychotics
Findling, R. L., McNamara, N. K., & Gracious, B. L. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.935 · Cited by 46
“Data from open prospective trials and case series suggest that risperidone may also be effective for the treatment of youths with schizophrenia, pervasive developmental disorders, bipolar disorder, Tourette’s disorder and as an adjunct in obsessive-compulsive disorder (Table 2) [26-52].”
BackgroundSelf-citation
Metadata
- Authors
- GRCEVICH, S. J., FINDLING, R. L., ROWANE, W. A., FRIEDMAN, L., & SCHULZ, S. C.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1996-01
- Volume
- 6
- Issue
- 4
- Pages
- 251-257
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2028118622
- Cited by
- 92
- References
- 1
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risperidone in the Treatment of Children and Adolescents with Schizophrenia: A Retrospective Study. https://app.cochat.ai/papers/10.1089/cap.1996.6.251
- The paper
- GRCEVICH, S. J., FINDLING, R. L., ROWANE, W. A., FRIEDMAN, L., & SCHULZ, S. C. (1996). Risperidone in the Treatment of Children and Adolescents with Schizophrenia: A Retrospective Study. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.1996.6.251
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.